3.34  0.05 (1.52%)		07-31 16:00
Open: 3.3 High: 3.38 Volume: 51,333		Pre. Close: 3.29 Low: 3.2 Market Cap: 3(M)

Short term
Mid term
Targets	6-month :	3.94	1-year :	4.61
Resists	First :	3.38	Second :	3.94
Pivot price	2.86
Supports	First :	2.81	Second :	2.46
MAs	MA(5) :	3.1	MA(20) :	2.86
	MA(100) :	2.14	MA(250) :	5.18
MACD	MACD :	0.1	Signal :	0.1
%K %D	K(14,3) :	95.1	D(3) :	92.9
RSI	RSI(14): 73.2
52-week	High :	11.5	Low :	1.3

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ ADIL ] has closed Bollinger Bands are 26% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	3.38 - 3.39	3.39 - 3.4
Low:	3.17 - 3.18	3.18 - 3.2
Close:	3.32 - 3.34	3.34 - 3.36

Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the treatment of alcohol use disorder. Beyond this flagship product, the company is also exploring drug candidates aimed at providing non-opioid pain relief and addressing a range of other medical conditions. Established in 2010, Adial Pharmaceuticals, Inc. is headquartered in Charlottesville, Virginia.

Tue, 28 Jul 2026
Adial Pharmaceuticals Inc (ADIL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Mon, 27 Jul 2026
Adial Pharmaceuticals Inc (ADIL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Mon, 27 Jul 2026
Adial Pharmaceuticals Inc (ADIL) Institutional Confidence - TradingKey

Fri, 24 Jul 2026
Adial Pharmaceuticals, Inc Revenue Breakdown – NASDAQ:ADIL - TradingView

Mon, 13 Jul 2026
Coastlands Capital LP (NASDAQ: ADIL) reports new insider share purchases - Stock Titan

Tue, 16 Jun 2026
Adial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE Financing - GlobeNewswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	2 (M)
Shares Float	1 (M)
Held by Insiders	4.3 (%)
Held by Institutions	28.2 (%)
Shares Short	244 (K)
Shares Short P.Month	347 (K)

EPS	-4.89
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	2.46
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-108.8 %
Return on Equity (ttm)	-266 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-3.45
Qtrly Earnings Growth	0 %
Operating Cash Flow	-7 (M)
Levered Free Cash Flow	-4 (M)

PE Ratio	-0.69
PEG Ratio	0
Price to Book value	1.35
Price to Sales	0
Price to Cash Flow	-1.13

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.